Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ8DF0
|
|||
| Drug Name |
Nedosiran
|
|||
| Synonyms |
DCR-PHXC
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Primary hyperoxaluria type 1 [ICD-11: 5C51.20] | Approved | [1] | |
| Hyperoxaluria [ICD-11: 5C51.2] | Phase 2 | [2] | ||
| Company |
Novo Nordisk; Dicerna Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | LDHA messenger RNA (LDHA mRNA) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215842 | |||
| REF 2 | ClinicalTrials.gov (NCT04580420) Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD (PHYOX7). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.